Akebia Therapeutics, Inc. today announced that John P. Butler , Chief Executive Officer, and David A. Spellman , Chief Financial Officer, will participate in the following schedule of investor conferences.
CAMBRIDGE, Mass., Sept. 1, 2021 /PRNewswire/ -- Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and David A. Spellman, Chief Financial Officer, will participate in the following schedule of investor conferences:
Where applicable, live webcasts of Akebia's fireside chats and presentations will be made available on the Investors section of the Company's website at https://ir.akebia.com . About Akebia Therapeutics Akebia Therapeutics Contact
SOURCE Akebia Therapeutics |
||
Company Codes: NASDAQ-NMS:AKBA |